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g.2013.0Abstract Mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes is a mito-
chondrial multisystem disorder. This disease has mainly been associated to the mitochondrial
DNA mutation A3243G located in the tRNA Leucine gene. In this article, we report the clinical,
radiological and molecular results of a 10 years old Child with the classical Mitochondrial enceph-
alomyopathy, lactic acidosis and stroke-like episodes phenotype. A 10 years old male Japanese child
presented with recurrent episodes of headache, nausea and vomiting of 5 years duration and hyper-
lactic acidemia. These episodes were associated with motor weakness on the right side, with difﬁ-
culties in language and memory and visual disturbance. Neurological examination revealed
generalized muscle weakness with mild right sided hemiparesis. The Magnetic Resonance Imaging
revealed infarct like lesions in the left occipital regions and the left medial temporal. The mitochon-
drial DNA mutations A3243G, T3271C and G13513A were tested using Polymerase Chain Reac-
tion- Restriction Fragment Length Polymorphism analysis and direct sequencing. The
heteroplasmic A3243G mutation was detected in the blood of the patient and his mother. L-Argi-
nine is reported to be beneﬁcial for the patients and a preventive treatment was given in the form
of arginine 500 mg twice per day.
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3.0021. Introduction
Mitochondria are key to many cellular processes. Oxidative
phosphorylation (OXPHOS) is one of the most important
mechanisms resulting in the production of cellular energy in
the form of adenosine triphosphate (ATP) [1,2].
Disorders of mitochondrial origin are a heterogeneous
group of diseases commonly manifesting in high-energy
demanding tissues such as muscles, brain, heart and nerves,
hence the name ‘‘mitochondrial encephalomyopathies’’ [3].in Shams University.
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(MCDs) are highly variable and the symptoms are often vague
and non-speciﬁc [4,5]. The clinical recognition of MCDs is
often challenging [6]. These diseases should be considered in
patients with apparently unexplained combinations of
symptoms and signs, especially if neurological features are
present [1].
The mitochondrial genome encodes 13 essential polypep-
tides of the OXPHOS system and the necessary RNAs machin-
ery. The remaining structural proteins and those involved in
import, assembly and mitochondrial DNA (mtDNA) replica-
tion are encoded by the nuclear DNA (nDNA) and are tar-
geted to the mitochondria [7].
More than 100 point mutations of mtDNA that are
known to cause mitochondrial dysfunction were identiﬁed
[8]. Mutations in mtDNA are more common than in nDNA.
mtDNA mutates 10–17 times faster than nDNA due to the
absence of chromatin and histones. Also the continuous gen-
eration of reactive oxygen species (ROS) and the lack of an
efﬁcient repairing mechanism further increase the mutation
rate [9]. Recent developments in the molecular diagnostics
allowed for the exploration of many of pathogenic muta-
tions, thus providing more clues about the molecular basis
of these disorders.
Mitochondrial genetics is characterized by maternal inheri-
tance, mitotic segregation, threshold effect and heteroplasmy
[10]. Since mitochondria are inherited only from the mother,
mtDNA defects result in pedigrees exhibiting a pattern of
maternal inheritance [7]. Because there are hundreds or even
thousands of mitochondria in each cell, mutation in mtDNA
may result in two populations of mtDNA (wild and mutant),
a condition known as heteroplasmy [7]. The phenotypic
expression of a mtDNA mutation is regulated by the threshold
effect, the mutant phenotype is expressed in heteroplasmic cells
only when the relative proportion of mutant mtDNAs reaches
a certain value [11]. A respiratory chain (RC) defect may be-
come manifest in some tissues, but not in others, if the number
of mutant mtDNA exceeds a certain critical threshold [12]. The
threshold level for the expression of mtDNA mutations is usu-
ally high (85–95%), but varies with different mutations. The
threshold varies among tissues, depending on the oxidative en-
ergy requirements [7].
Because both mtDNA replication and mitochondrial divi-
sion are random processes unrelated to cell division, a dividing
cell donates variable numbers of mitochondria and mtDNAs
to its progeny [11]. This process, known as mitotic segregation,
can be important clinically if a patient harbors heteroplasmic
populations in tissues, resulting in changing mutation loads
in consecutive generations and increasing the phenotypic vari-
ation of MCDs [7].
Mitochondrial encephalomyopathy, lactic acidosis and
stroke-like episodes (MELAS) syndrome is one of the most
frequently occurring MCDs [3]. Patients with MELAS syn-
drome are usually normal at birth and develop normally dur-
ing the ﬁrst years of life [1]. The patients often have episodes of
vomiting with severe headache [3] leading to somnolence and
coma [1]. Some of these episodes may lead to severe general-
ized seizures with stroke-like episodes of hemiparesis [3]. Atax-
ia [13], dementia [14], muscle weakness, sensorineural deafness,
exercise intolerance [1] and diabetes mellitus are frequently
seen [15]. Cardiomyopathy may also develop in the late stages
of the disease [1].Although nearly 80% of the coding part of the mtDNA is
allocated to protein-coding genes and around 10% to tRNA
genes, most of the pathogenic point mutations so far described
affect tRNA genes [16]. Pathogenic mutations have been iden-
tiﬁed in most of the 22 tRNA genes, however, some tRNA
genes are more frequently affected than others. Among these
are the tRNA Leucine (Leu), tRNA –Lysine (Lys) and tRNA-
Isoleucine (Ile) .The most common tRNA mutation is tRNA
Leu A3243G, which is typically associated with MELAS syn-
drome [17]. Other tRNA Leu mutations (G3244A, T3258C,
C3256T, T3271C, T3291C), mutations in tRNA Val [18] and
tRNA His [19] were also found to be associated with the
MELAS syndrome [8].
Molecular causes of MELAS other than tRNA mutations
have been described [20]. Mutations in the nicotinamide ade-
nine dinucleotide dehydrogenase (NADH) 5 gene of mitochon-
drial DNA are important. The G13513A mutation emerged as
a hotspot. It is therefore important to consider this mutation in
patients with Leigh Syndrome (LS), or overlapping features of
the MELAS and leigh syndromes [20].
In this article, we report the clinical, radiological and
molecular results of a 10 year old child with the classical
MELAS phenotype.
2. Case report
A 10 year old male child, born to a Japanese father and Chi-
nese mother, presented to the Inherited Metabolic Disease
Unit at the Cairo University Children’s hospital with recurrent
episodes of headache, nausea and vomiting of 5 years dura-
tion. These episodes were associated with motor weakness on
the right side with difﬁculties in language and memory and vi-
sual disturbance, mostly right sided homonymous hemianopia.
Neurological examination revealed generalized muscle weak-
ness, with mild right sided hemiparesis. These clinical manifes-
tations were reliable to the Magnetic Resonance Imaging
(MRI) showing infarction of left posterior parietal, left occip-
ital and left medial temporal regions, without visible vascular
abnormality at the Magnetic Resonance Angiography
(MRA) (Fig. 1A, B). Laboratory Investigations revealed
hyperlactic acidemia and a discrete increase in hepatic trans-
aminases. The patient was clinically suspected to have MELAS
syndrome .The mother reported that her brother suffered from
the same clinical picture and died by the age of 19 years but the
cause of death is not clear (Fig. 2).
3. Methods
3.1. Ethical issue
Written informed consent was obtained from the parents for
all the procedures performed.
3.2. DNA extraction from the whole blood samples
Total genomic nDNA and mtDNA were extracted from
peripheral blood leukocytes of the patient and his mother
and healthy control age and sex matched child. The control
was attending the hospital for other different reasons. He
reported no symptomatic metabolic, genetic, or ocular disor-
ders regarding family history, past medical problems, and
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Figure 1 MRI brain showing infarction of the left medial temporal (A) and left occipital regions (B) (arrows).
Figure 2 Family pedigree of the studied patient. P: Proband.
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available DNA isolation kits (QIAamp DNA Blood Mini
Kit) from Qiagen (TM), Germany, and following the manufac-
turer’s instructions.
3.3. Polymerase chain reaction–restriction fragment length
polymorphism (PCR–RFLP) analysis
The most common point mutations related to MELAS
A3243G, T3271C, G13513A were tested as previously de-
scribed [21,22,2]. The PCR products were digested using
HaeIII, DraI and BpuAI, respectively. Digested products were
separated at 120 V for 20–30 min by 12% polyacrylamide gel
electrophoresis using the BioRad Mini-Protean tetra gel
system (Bio-Rad, Hercules, CA, USA) and stained by
0.5 mg/ml with ethidium bromide. A 50 bp DNA ladder
(MBI Fermentas) was used as a size marker. The gel was
visualized using UV transilluminator (BIORAD, USA).The
wild and mutant patterns are shown in Table 1.Table 1 Restriction analysis products.
Mutation PCR product size Wild type (bp) Mutant type (bp)
A3243G 230 166 + 64 93 + 73 + 64
T3271C 145 123 + 22 145
G13513A 210 189 + 21 210
Bp: base pair.3.4. Direct sequencing
To conﬁrm the presence of the mutation A3243G, direct
sequencing was performed using the Applied Biosystems
(ABI) automated Sequencer (ABI 310, Applied Biosystems,
Foster City, CA) and the dideoxy chain terminators kit
(BigDye Terminator Cycle Sequencing Reaction Kit; ABI).
The sequence was compared to the revised Cambridge refer-
ence sequence [24].
4. Results
PCR/RFLP analysis for three MELAS associated mtDNA
mutations revealed positive heteroplasmic pattern for the
A3243G mutation in the patient and his mother (Fig. 3).
The mutation was conﬁrmed by direct sequencing (Fig. 4).
The T3271C and the G13513A mutations were negative.
5. Discussion
MELAS syndrome is one of the most common clinical entities
caused by mtDNA mutations [27,28]. A diagnosis of MELAS
is based on clinical features, including recurrent stroke-like1          2        3        4           5
73 bp
64 bp
Figure 3 RFLP analysis showing positive 3243 heteroplasmic
mutation in the patient and his mother along with negative
control. Lane 1: 50 base pair (bp) ladder, lane 2: mother, lane 3:
negative control, lane 4: the patient and lane 5: uncut PCR
product.
Figure 4 A3243G mutation conﬁrmed by direct sequencing
(arrow).
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malities of infarct-like lesions that are not conﬁned to the ma-
jor vascular territories [30] and biochemical evidence for
mitochondrial defects, such as lactic acidosis or Ragged Red
Fibers (RRF) in the muscle biopsy [31,32]. The proband of
the present study expressed the classical picture of MELAS
syndrome.
MELAS usually affects patients by the age of 5–15 years
[33]. In concordance with the present study, the proband
started to manifest by the age of 5 years.
The high plasma lactate in the proband was in agreement
with the fact that high lactate is a marker of MCDs [3,7,34].
In MELAS, lactic acidosis correlates with the severity of neu-
rological impairment [35].
Cerebral imaging plays a central role in further diagnostics
relating to suspected or certain MCDs in children [36]. Cortical
changes are especially prominent in MELAS and Alpers syn-
drome [37]. Infarct-like lesions not conﬁned to vascular territo-
ries are the imaging hallmark of MELAS syndrome [35].
Concomitant with these ﬁndings, the MRI of the proband of
the present study showed infarct like lesions of the left poster-
ior parietal, left occipital and left medial temporal regions,
without visible vascular abnormality at the Magnetic Reso-
nance Angiography.
At least 30 kinds of gene mutations had been reported in
MELAS patients (www.mitomap.org). The A3243G mutation
is found in 80% of the patients [15,27,38,39]. The A3243G
MELAS mutation is also found in some patients with mater-
nally inherited diabetes/deafness syndrome (MIDD) [40] and
many other neuromuscular disorders [41]. In a cohort of
1340 unrelated Chinese patients suspected of having mitochon-
drial disease, the detection rate of A3243G was 9.4%, and it
was the most frequent mutation (79.3%) in the samples with
mtDNA mutations. This high detection rate suggests the
importance of this mutation especially in Chinese patients with
MELAS [42]. In the present study, the proband and his mother
were positive for the 3243 mutation conﬁrming the theory of
maternal inheritance of MCDs. The mother and his sister were
phenotypically normal and this could be explained by the pe-
culiar genetics of MCDs (threshold effect).
A similar study had been conducted by Qi et al. [43] to
investigate the spectrum of common mitochondrial mutations
in Northern China during the years of 2000–2005. Five hun-
dred and 52 patients were clinically diagnosed as MELAS.
The A3243G mutation was detected in 10% of the cases.
Ten Brazilian patients suffering from MELAS were studied
by Lorenzoni et al. [39]. Similar to the present study, MRIrevealed a stroke-like pattern in all patients and molecular
analysis of tRNA Leu gene by PCR/RLFP showed the
A3243G mutation in 40% of the patients. They recommended
that PCR/RLFP for the A3243G mutation must be the ﬁrst
simple molecular test when MELAS is suspected.
The T3271C mutation is the second most common muta-
tion [39], presenting in about 10% of MELAS patients
[44,45], predominantly in Japanese patients [15,46]. This
mutation was reported in only 11 MELAS patients outside
Japan (North America, Europe and Brazil) [15,38,47,48]. This
mutation was not detected in 522 Chinese patients with
encephalomyopathy, nor in 114 clinically diagnosed MELAS
patients [49]. This mutation was negative in the proband of
the present study (Chinese mother), this conﬁrms the ﬁnding
that T3271C may be uncommon in Chinese patients with
MELAS and mitochondrial encephalomyopathy [49].
G13513A mutation was also reported in MELAS patients
[20,23]. It was described in 21 patients; seven with MELAS
[23,50–52] and 14 with LS [53–57]. Despite being negative in
the proband of the present study, this mutation had been
tested in our study in agreement with several authors who rec-
ommended that this mutation should be routinely tested in pa-
tients with MELAS even in the absence of a biochemical
complex I deﬁciency [20,53,56,58].
Contrary to the results of the present study, Shanske et al.
[58] suggested that G13513A mutation is a common cause of
MELAS even in the absence of marked complex I deﬁciency,
clear history of maternal inheritance or pathological evidence
in muscle. However, many studies reported that 13513 is a rare
cause of MELAS syndrome or mitochondrial encephalomyop-
athy in Chinese patients [46,49,59].
Many treatment options of RC disorders had been recently
reviewed [60]. Several lines of treatment were proposed for the
treatment of MELAS patients [59]. L-Arginine was reported to
be one of the promising therapeutic options for MELAS pa-
tients [60]. Accordingly a preventive treatment was given to
the proband described in the present study in the form of argi-
nine 500 mg twice per day.Acknowledgements
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